Emicizumab is well tolerated and effective in people with congenital haemophila A regardless of age severity of disease or inhibitor status a scoping review

Simple item page
dc.article.end-page17en
dc.article.start-page1en
dc.citation.doi10.1016/J.RPTH.2024.102415en
dc.contributor.authorG Youngen
dc.contributor.authorS Pipeen
dc.contributor.authorG Keneten
dc.contributor.authorJ Oldenburgen
dc.contributor.authorE et alen
dc.contributor.authorJohnny Mahlanguen
dc.date.accessioned2024-10-17T10:13:14Z
dc.date.available2024-10-17T10:13:14Z
dc.facultyFACULTY OF HEALTH SCIENCESen
dc.identifier.citationWOSen
dc.identifier.issn2475-0379en
dc.identifier.urihttps://hdl.handle.net/10539/41678
dc.journal.titleEmicizumab is well tolerated and effective in people with congenital haemophila A regardless of age severity of disease or inhibitor status a scoping reviewen
dc.journal.volume8en
dc.publisherWILEY-BLACKWELLen
dc.titleEmicizumab is well tolerated and effective in people with congenital haemophila A regardless of age severity of disease or inhibitor status a scoping reviewen
dc.typeJournal Articleen
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Journal Article.pdf
Size:
1.1 MB
Format:
Adobe Portable Document Format
Description:
Bitstream uploaded by REST Client
Download
Collections
Academic Wits Research Outputs (All submissions)